GO:0016285 alanyl aminopeptidase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016285 (alanyl aminopeptidase activity) describes the catalysis of N-terminal amino acid release, preferentially alanine, from peptides, amides and arylamides.
• The term covers multiple synonyms including membrane alanyl aminopeptidase, puromycin-sensitive aminopeptidase, cytosol alanyl aminopeptidase and arylamidase activity.
• Alanyl aminopeptidase activity is measurable in diverse tissues such as nasal mucosa, cerebrospinal fluid, retina and intestine.
• Decreased alanyl aminopeptidase activity in cerebrospinal fluid has been reported in Alzheimer patients.
• Alanyl aminopeptidase N from Anopheles stephensi is a candidate malaria transmission-blocking antigen.
• CRISPR knockout, point mutation, knock-in and overexpression models enable causal testing of alanyl aminopeptidase genes.
Description
Alanyl aminopeptidase activity (GO:0016285) is a molecular function defined as the catalysis of the release of an N-terminal amino acid, preferentially alanine, from a wide range of peptides, amides and arylamides. This activity is attributed to several enzymes, most prominently membrane alanyl aminopeptidase (aminopeptidase N, ANPEP) and puromycin-sensitive aminopeptidase (NPEPPS), which share the ability to cleave N-terminal residues with a preference for alanine. The term is widely used in enzymology, neurobiology and immunology because it captures a conserved proteolytic function that participates in peptide processing, antigen presentation and extracellular matrix remodeling. Researchers study GO:0016285 because altered alanyl aminopeptidase activity has been linked to human disease and physiological adaptation. For example, a decrease in alanyl-aminopeptidase activity has been reported in the cerebrospinal fluid of Alzheimer patients, while the same activity in the frontal cortex of aged rats did not change, suggesting region-specific regulation. In the retina, alanyl-aminopeptidase activity is influenced by light/dark cycles in a left-right asymmetrical manner. In the intestine of the marine fish Mugil liza, alanyl aminopeptidase activity responds differentially to dopamine and histamine. These findings illustrate that GO:0016285 is not a static housekeeping function but a dynamically regulated activity relevant to neuroscience, chronobiology and comparative physiology. From a translational perspective, alanyl aminopeptidase activity is also relevant to infectious disease and oncology. Anopheles stephensi alanyl aminopeptidase N formulated with MPL, CpG and QS21 adjuvants showed malaria transmission-blocking activity, and aminopeptidase N is a reviewed target in human disease biochemistry. In nasal mucosa, aminopeptidase activity has been characterized in the context of allergy. Together, these studies position GO:0016285 as a multifunctional activity at the interface of peptide metabolism, immunity and disease.
alanyl aminopeptidase activity At A Glance
| GO ID | GO:0016285 |
|---|---|
| GO term | alanyl aminopeptidase activity |
| Ontology | molecular_function |
| Definition | Catalysis of the release of an N-terminal amino acid, preferentially alanine, from a wide range of peptides, amides and arylamides. |
| Synonym | aminopolypeptidase activity; arylamidase activity; cytosol alanyl aminopeptidase activity; cytosol aminopeptidase III activity; human liver aminopeptidase; liver aminopeptidase activity; membrane alanine aminopeptidase; membrane alanyl aminopeptidase; puromycin-sensitive aminopeptidase activity; soluble alanyl aminopeptidase activity; thiol-activated aminopeptidase activity |
| Major function | N-terminal peptide trimming with preference for alanine |
| Substrate range | Peptides, amides, arylamides |
| Representative enzymes | Membrane alanyl aminopeptidase (ANPEP), puromycin-sensitive aminopeptidase (NPEPPS) |
| Tissue examples | Nasal mucosa, cerebrospinal fluid, retina, intestine |
| Disease relevance | Alzheimer disease, malaria transmission, allergy, cancer |
What Is GO:0016285?
GO:0016285, alanyl aminopeptidase activity, is defined as the catalysis of the release of an N-terminal amino acid, preferentially alanine, from a wide range of peptides, amides and arylamides. In practical terms, it is a proteolytic activity that trims the first amino acid from the N-terminus of a substrate, with a strong preference for alanine, although other residues can be cleaved depending on the enzyme and substrate. The term encompasses synonyms such as aminopolypeptidase activity, arylamidase activity, cytosol alanyl aminopeptidase activity, membrane alanine aminopeptidase, puromycin-sensitive aminopeptidase activity and thiol-activated aminopeptidase activity.
Why Is alanyl aminopeptidase activity Important in Cell Biology?
GO:0016285 is important because it defines a conserved proteolytic activity that shapes the N-terminome of cells and body fluids, influencing peptide hormone processing, antigen presentation and extracellular matrix turnover. Its measurement in cerebrospinal fluid, nasal mucosa, retina and intestine has provided disease-relevant and physiological insights, including decreased activity in Alzheimer patients, light-cycle-dependent asymmetry in the retina, and differential responses to neurotransmitters in fish intestine. The activity is also a target of vaccine and drug development, as illustrated by malaria transmission-blocking studies with Anopheles stephensi alanyl aminopeptidase N and by the broader disease implications of mammalian aminopeptidase N.
• Provides a defined molecular function for N-terminal peptide trimming with alanine preference.
• Enables quantitative comparison of aminopeptidase activity across tissues and species.
• Links to Alzheimer disease through decreased cerebrospinal fluid alanyl-aminopeptidase activity.
• Shows age-related stability in rat frontal cortex, contrasting with other aminopeptidases.
• Supports malaria transmission-blocking vaccine research targeting Anopheles alanyl aminopeptidase N.
• Relevant to allergy research through aminopeptidase activity in human nasal mucosa.
• Involved in retinal chronobiology with asymmetrical left-right responses to light.
• Provides a functional readout for CRISPR knockout and overexpression studies of ANPEP and NPEPPS.
• Connects to cancer biology through aminopeptidase N as a reviewed disease target.
• Offers a biochemical endpoint for neurotransmitter modulation studies in intestine.
Molecular Mechanism of alanyl aminopeptidase activity
Substrate recognition and N-terminal binding
In simple terms: The enzyme grabs the end of a peptide and positions the first amino acid for cutting.
Alanyl aminopeptidase activity begins with binding of the substrate's N-terminus, positioning the first amino acid in the catalytic site. The activity preferentially releases alanine, but the QuickGO definition explicitly states that a wide range of peptides, amides and arylamides can serve as substrates. This broad substrate range is why synonyms such as arylamidase activity and aminopolypeptidase activity are grouped under GO:0016285.
Catalytic cleavage and product release
In simple terms: The enzyme cuts off the first amino acid and releases it.
Following substrate binding, the enzyme catalyzes hydrolysis of the N-terminal peptide bond, releasing a free amino acid and a shortened peptide. The reaction is described as catalysis of the release of an N-terminal amino acid, preferentially alanine, from peptides, amides and arylamides. This catalytic step is the defining event of GO:0016285 and is measured biochemically in tissues such as nasal mucosa and cerebrospinal fluid.
Isoform diversity and subcellular context
In simple terms: Different versions of the enzyme work in different parts of the cell.
GO:0016285 encompasses both membrane-bound and soluble forms, reflected in synonyms such as membrane alanine aminopeptidase, cytosol alanyl aminopeptidase activity and soluble alanyl aminopeptidase activity. Membrane alanyl aminopeptidase (ANPEP) is a well-characterized cell-surface enzyme, whereas puromycin-sensitive aminopeptidase (NPEPPS) is a cytosolic enzyme. This diversity means that the same GO term can be assigned to enzymes with distinct localization and regulation.
Regulation by physiological cues
In simple terms: The activity changes with light, neurotransmitters and age.
Alanyl aminopeptidase activity is dynamically regulated. In adult male rat retinas, a standard light/dark cycle and constant light conditions asymmetrically influence alanyl-aminopeptidase activity of the left and right retinas. In the intestine of juvenile Mugil liza, dopamine and histamine differentially affect alanyl aminopeptidase activity. In aged rat frontal cortex, alanyl-aminopeptidase activity did not decrease, unlike cytosolic aspartyl-aminopeptidase. These examples show that GO:0016285 is subject to tissue-specific and stimulus-specific regulation.
Measurement and inhibition
In simple terms: Scientists measure the activity with synthetic substrates and inhibitors.
Alanyl aminopeptidase activity is commonly assayed using arylamide substrates, consistent with the definition's inclusion of arylamides. The synonym puromycin-sensitive aminopeptidase activity indicates that some forms are inhibited by puromycin. In human nasal mucosa, aminopeptidase activity has been characterized biochemically, and in cerebrospinal fluid, alanyl-aminopeptidase activity was measured in Alzheimer patients. These assays provide the experimental basis for assigning GO:0016285 to specific enzymes and samples.
Key Genes Involved in GO:0016285 alanyl aminopeptidase activity
The following genes and proteins are directly associated with alanyl aminopeptidase activity (GO:0016285) or are used as experimental models to study it.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ANPEP | Membrane alanyl aminopeptidase (aminopeptidase N) with alanyl aminopeptidase activity | Reviewed target in human disease biochemistry and malaria transmission-blocking research |
| NPEPPS | Puromycin-sensitive aminopeptidase with cytosolic alanyl aminopeptidase activity | Prototype for the puromycin-sensitive synonym of GO:0016285 |
| LNPEP | Leucyl/cystinyl aminopeptidase, related aminopeptidase family member | Comparative studies of aminopeptidase substrate specificity |
| ENPEP | Glutamyl aminopeptidase, related M1 family enzyme | Family comparison for N-terminal trimming |
| ERAP1 | Endoplasmic reticulum aminopeptidase 1, peptide trimming in antigen presentation | Mechanistic comparison of peptide trimming |
| ERAP2 | Endoplasmic reticulum aminopeptidase 2, peptide trimming | Mechanistic comparison of peptide trimming |
| ANPEP (Anopheles stephensi) | Mosquito alanyl aminopeptidase N antigen | Malaria transmission-blocking vaccine development |
| MUC16 | Mucin 16, context for bispecific antibody studies | Ovarian cancer therapeutic context |
| CD3E | T cell engager component in bispecific antibodies | Immunotherapy context |
| REN | Renin, unrelated control for tissue-specific enzyme studies | Control for tissue enzyme activity comparisons |
| ACE2 | Angiotensin-converting enzyme 2, related peptidase | Comparative peptidase biology |
| MME | Neprilysin, related membrane peptidase | Comparative peptidase biology |
| DPP4 | Dipeptidyl peptidase 4, related peptidase | Comparative peptidase biology |
| CTSB | Cathepsin B, lysosomal peptidase | Comparative proteolytic context |
| CTSD | Cathepsin D, lysosomal peptidase | Comparative proteolytic context |
| PSMA | Prostate-specific membrane antigen, related peptidase | Comparative peptidase biology |
| GAPDH | Housekeeping control for expression studies | Normalization in expression experiments |
| ACTB | Housekeeping control for expression studies | Normalization in expression experiments |
How Is alanyl aminopeptidase activity Regulated?
Alanyl aminopeptidase activity is regulated by physiological and environmental cues rather than by a single dedicated pathway. In the retina, light/dark cycles and constant light conditions asymmetrically influence alanyl-aminopeptidase activity in the left and right retinas of adult male rats. In the intestine of juvenile Mugil liza, dopamine and histamine differentially modulate alanyl aminopeptidase activity. Ageing studies in rat frontal cortex showed that alanyl-aminopeptidase activity was not decreased, unlike cytosolic aspartyl-aminopeptidase, indicating selective regulation of aminopeptidase classes during ageing. In human disease contexts, aminopeptidase N is reviewed as a regulated enzyme with implications in multiple pathologies. These observations support a model in which GO:0016285 is controlled at the level of enzyme abundance, localization and local substrate availability.
alanyl aminopeptidase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ANPEP | Alzheimer disease and neurodegeneration | Human cell lines with ANPEP knockout and alanyl aminopeptidase activity assays |
| ANPEP (Anopheles stephensi) | Malaria transmission | Mosquito alanyl aminopeptidase N antigen formulations in transmission-blocking assays |
| NPEPPS | Puromycin-sensitive aminopeptidase biology | NPEPPS knockout cells with arylamide-based activity assays |
| ANPEP | Allergy and nasal mucosa inflammation | Primary nasal epithelial cells or nasal mucosa explants |
| ANPEP | Cancer and immunotherapy | Ovarian cancer models with bispecific antibody evaluation |
Alanyl aminopeptidase activity in Alzheimer disease
Alanyl-aminopeptidase activity is decreased in the cerebrospinal fluid of Alzheimer patients. This finding suggests that reduced N-terminal peptide trimming may contribute to altered peptide homeostasis in neurodegeneration. In contrast, alanyl-aminopeptidase activity in the frontal cortex of aged rats did not decrease, indicating that not all brain regions or aminopeptidase classes are equally affected during ageing. Together, these studies link GO:0016285 to neurodegenerative disease biology and highlight the importance of fluid versus tissue measurements.
Alanyl aminopeptidase N and malaria transmission blocking
Anopheles stephensi alanyl aminopeptidase N is a candidate antigen for malaria transmission-blocking vaccines. Formulation with MPL, CpG and QS21 adjuvants induced transmission-blocking activity in preclinical studies. This work illustrates how a protein carrying alanyl aminopeptidase activity can be exploited as an immunogen to interrupt parasite development in the mosquito vector. The broader review of mammalian aminopeptidase N also discusses its physiological and disease implications, supporting translational interest in this enzyme family.
Alanyl aminopeptidase activity in allergy and nasal mucosa
Aminopeptidase activity has been characterized in human nasal mucosa, a tissue directly relevant to allergic rhinitis and airway inflammation. The presence of alanyl aminopeptidase activity in nasal mucosa suggests a role in local peptide processing and possibly in the degradation of inflammatory peptides. This work provides a baseline for studying how GO:0016285 contributes to mucosal immunity and allergy.
Alanyl aminopeptidase activity in cancer and immunotherapy
Aminopeptidase N is reviewed as a multifunctional enzyme with implications in human diseases including cancer. In parallel, bispecific T cell-engaging antibodies targeting Mucin 16 have been developed for ovarian cancer, illustrating the broader therapeutic landscape in which peptidase and surface antigens are evaluated. Although direct evidence linking GO:0016285 to ovarian cancer is limited in the provided literature, the reviewed disease implications of aminopeptidase N support further investigation.
From alanyl aminopeptidase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ANPEP reduce alanyl aminopeptidase activity? | ANPEP knockout cell line |
| Does a catalytic-site mutation abolish alanyl aminopeptidase activity? | Point-mutation knock-in of catalytic residue |
| Does tagging ANPEP alter its localization? | Tagged knock-in with fluorescent or epitope tag |
| Does overexpression increase N-terminal peptide trimming? | ANPEP overexpression cell line |
| Which genes regulate alanyl aminopeptidase activity? | CRISPR library screening |
| Is alanyl aminopeptidase activity altered in Alzheimer models? | Patient-derived cells or cerebrospinal fluid assays |
| Does light cycle affect retinal alanyl aminopeptidase activity? | In vivo rodent retina model |
How to Study the alanyl aminopeptidase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Arylamide-based activity assay | Alanyl aminopeptidase enzymatic activity | Tissue and cell lysate profiling |
| Cerebrospinal fluid assay | Soluble alanyl-aminopeptidase activity | Alzheimer disease biomarker studies |
| Retinal activity assay | Left-right asymmetric activity | Chronobiology and light-cycle studies |
| Intestinal activity assay | Neurotransmitter modulation of activity | Comparative physiology in fish |
| CRISPR knockout | Loss of gene function | Causal testing of ANPEP and NPEPPS |
| Point mutation knock-in | Catalytic residue requirement | Separation of activity from other functions |
| Overexpression | Gain of activity | Peptide trimming and substrate studies |
| Transmission-blocking assay | Mosquito infection reduction | Malaria vaccine development |
Biochemical activity assays
Alanyl aminopeptidase activity is measured using synthetic arylamide substrates, consistent with the definition's inclusion of arylamides. These assays have been applied to human nasal mucosa and cerebrospinal fluid from Alzheimer patients. They provide direct functional readouts for GO:0016285 and are suitable for comparing tissues, cell lines and mutant enzymes.
Tissue and fluid profiling
Profiling alanyl aminopeptidase activity across tissues and body fluids reveals physiological regulation. Studies in rat retina showed asymmetrical left-right responses to light/dark cycles, while studies in Mugil liza intestine showed differential responses to dopamine and histamine. Ageing studies in rat frontal cortex compared alanyl-aminopeptidase with aspartyl-aminopeptidase activity. Such profiling is essential for understanding the tissue-specific roles of GO:0016285.
Genetic and CRISPR-based perturbation
CRISPR knockout, point mutation, knock-in and overexpression models allow causal testing of genes carrying alanyl aminopeptidase activity. Knockout of ANPEP or NPEPPS can reveal which enzyme contributes to measured activity in a given cell type. Point mutations of catalytic residues can separate enzymatic activity from non-catalytic functions. These approaches complement biochemical assays and are central to functional genomics of GO:0016285.
Immunological and vaccine-oriented assays
Because Anopheles stephensi alanyl aminopeptidase N is a transmission-blocking antigen, immunological assays such as antibody titers and membrane-feeding assays are used to evaluate vaccine formulations. These methods connect GO:0016285 to infectious disease research and require recombinant antigen production and adjuvant formulation. The broader review of aminopeptidase N also supports its evaluation as a therapeutic target.
How CRISPR Can Be Used to Study GO:0016285 alanyl aminopeptidase activity
Knockout
CRISPR knockout of ANPEP or NPEPPS is used to eliminate alanyl aminopeptidase activity and determine which enzyme accounts for measured activity in a given cell type. Knockout models are essential for linking GO:0016285 to downstream phenotypes such as peptide processing, antigen presentation or cell surface remodeling. In disease contexts, knockout cells can be challenged with substrates or stressors to test whether the activity is protective or pathogenic.
Point Mutation
Point mutation knock-in of catalytic residues allows researchers to abolish enzymatic activity while preserving protein expression and localization. This is critical for distinguishing the catalytic function of GO:0016285 from non-catalytic scaffolding roles of the same protein. Point mutants can be compared with wild-type and knockout cells in activity assays and phenotypic screens.
Knock-in
Tagged knock-in of ANPEP or NPEPPS with fluorescent or epitope tags enables real-time localization and interaction studies without altering endogenous regulation. Knock-in of disease-associated variants can model how sequence changes affect alanyl aminopeptidase activity. These models are valuable for connecting genotype to biochemical function in GO:0016285 research.
Overexpression
Overexpression of ANPEP or NPEPPS increases alanyl aminopeptidase activity and can reveal substrate preferences and saturation effects. Overexpression models are useful for producing recombinant enzyme for biochemical characterization and for testing inhibitors. They also complement knockout studies by providing gain-of-function evidence for the role of GO:0016285 in cellular processes.
How EDITGENE Supports alanyl aminopeptidase activity Research
Researchers studying alanyl aminopeptidase activity-related genes often need to determine whether a candidate gene is causally involved in the measured activity or in a downstream phenotype. EDITGENE provides CRISPR-based cell model services that enable knockout, point mutation, knock-in, overexpression and library screening for genes such as ANPEP and NPEPPS, supporting rigorous functional studies of GO:0016285.
Contact EDITGENE today to design your custom CRISPR model for alanyl aminopeptidase activity research.
Frequently Asked Questions About alanyl aminopeptidase activity
What is alanyl aminopeptidase activity?
Alanyl aminopeptidase activity (GO:0016285) is the catalysis of the release of an N-terminal amino acid, preferentially alanine, from a wide range of peptides, amides and arylamides.
What genes are involved in alanyl aminopeptidase activity?
Key genes include ANPEP, which encodes membrane alanyl aminopeptidase, and NPEPPS, which encodes puromycin-sensitive aminopeptidase, both of which carry this activity.
What is the GO ID for alanyl aminopeptidase activity?
The Gene Ontology ID is GO:0016285, and it belongs to the molecular_function aspect.
Is alanyl aminopeptidase activity decreased in Alzheimer disease?
Yes, alanyl-aminopeptidase activity has been reported to be decreased in the cerebrospinal fluid of Alzheimer patients.
Does light exposure affect alanyl aminopeptidase activity in the retina?
Yes, a standard light/dark cycle and constant light conditions asymmetrically influence alanyl-aminopeptidase activity of the left and right retinas in adult male rats.
Is alanyl aminopeptidase activity changed during ageing?
In the frontal cortex of aged rats, alanyl-aminopeptidase activity did not decrease, unlike cytosolic aspartyl-aminopeptidase activity.
Can alanyl aminopeptidase N be used for malaria vaccines?
Anopheles stephensi alanyl aminopeptidase N formulated with MPL, CpG and QS21 adjuvants showed malaria transmission-blocking activity in preclinical studies.
How is alanyl aminopeptidase activity measured?
It is commonly measured using arylamide substrates, consistent with the definition that includes arylamides, and has been assayed in nasal mucosa and cerebrospinal fluid.
Is alanyl aminopeptidase activity present in the intestine?
Yes, alanyl aminopeptidase activity has been measured in the intestine of juvenile Mugil liza, where it responds differentially to dopamine and histamine.
What CRISPR models are used to study alanyl aminopeptidase activity?
Knockout, point mutation, knock-in and overexpression models of genes such as ANPEP and NPEPPS are used to test the causal role of this activity.
Conclusion
GO:0016285, alanyl aminopeptidase activity, defines a conserved proteolytic function that trims N-terminal amino acids with a preference for alanine from peptides, amides and arylamides. Its measurement across tissues and fluids has revealed disease associations such as decreased activity in Alzheimer cerebrospinal fluid, light-dependent asymmetry in the retina, and neurotransmitter responsiveness in fish intestine. The activity is also a target for malaria transmission-blocking vaccine development and is reviewed as relevant to multiple human diseases. CRISPR-based knockout, point mutation, knock-in and overexpression models provide the tools needed to move from correlation to causation in alanyl aminopeptidase research. By combining precise genetic perturbation with biochemical activity assays and disease-relevant models, researchers can clarify how GO:0016285 contributes to normal physiology and pathology.
References
- 1. Domínguez-Vías G et al.. 2020. Asymmetrical influence of a standard light/dark cycle and constant light conditions on the alanyl-aminopeptidase activity of the left and right retinas in adult male rats.. Exp Eye Res 198:108149 PMID: 32693084
- 2. Pourhashem Z et al.. 2024. Malaria transmission blocking activity of Anopheles stephensi alanyl aminopeptidase N antigen formulated with MPL, CpG, and QS21 adjuvants.. PLoS One 19(7):e0306664 PMID: 38968270
- 3. Crawford A et al.. 2019. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.. Sci Transl Med 11(497) PMID: 31217340
- 4. Ohkubo K et al.. 1998. Aminopeptidase activity in human nasal mucosa.. J Allergy Clin Immunol 102(5):741-50 PMID: 9819290
- 5. Iribar MC et al.. 1998. Alanyl-aminopeptidase activity decrease in cerebrospinal fluid of Alzheimer patients.. Dement Geriatr Cogn Disord 9(1):44-9 PMID: 9469265
- 6. Iribar C et al.. 1995. Decrease in cytosolic Aspartyl-aminopeptidase but not in Alanyl-aminopeptidase activity in the frontal cortex of the aged rat.. Brain Res 687(1-2):211-3 PMID: 7583308
- 7. Pascual-Alonso I et al.. 2026. Biochemistry, physiology and implications in human diseases of mammalian aminopeptidase N: A review.. Int J Biol Macromol 350:151030 PMID: 41724302
- 8. Albanesi C et al.. 2025. Disaccharidases and alanyl aminopeptidase activities in intestine of a marine estuarine-dependent fish: differential responses to dopamine and histamine in juveniles of Mugil liza (Actiopterygii: Mugilidae).. J Comp Physiol B 195(4):439-443 PMID: 40603696
